固定制剂拉坦噻吗滴眼液降眼压效果的短期临床观察
被引量:3
摘要
前列腺素类滴眼液的出现为药物治疗青光眼提供了新的途径,其降眼压机制主要是通过增加葡萄膜巩膜房水引流,而不减少房水生成。噻吗洛尔眼液是一种非选择性的β-肾上腺素能受体阻滞剂,其降眼压作用原理是降低眼房水的形成能力,抑制眼压上升。
出处
《中国眼耳鼻喉科杂志》
2012年第1期62-63,共2页
Chinese Journal of Ophthalmology and Otorhinolaryngology
参考文献12
-
1Higginbotham E J,Feldman R,Stiles M,et al.Latanoprost and timolol combination therapy vs monotherapy:one-year randomized trial[J].Arch Ophthalmol,2002,120(7):915-922.
-
2European Glaucoma Society Terminology and Guidelines for Glaucoma.Savona,Italy:DOGMA,Ⅱ 2008[http://www.eugs.org/eng/EGS_guidelines.asp],Accessed September 3,2010.
-
3Schwenn O,Heckmann B,Guzy C,et al.Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension:a prospective,observational,noninterventional study[J].BMC Ophthalmol,2010,10:21.
-
4Kass MA,Heuer DK,Higginbotham E J,et al.The Ocular Hypertension Treatment Study:a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma[J].Arch Ophthalmol,2002,120 (6):701-713.
-
5AGIS Investigators.The Advanced Glaucoma Intervention Study (AGIS):7:The relationship between control of intraocular pressure and visual field deterioration[J].Am J Ophthalmol,2000,130(4):429-440.
-
6Collaborative Normal-Tension Glaucoma Study Group.The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma[J].Am J Ophthalmol,1998,126(4):498-505.
-
7Heijl A,Leske MC,Bengtsson B,et al.Early Manifest Glaucoma Trial Group:Reduction of intraocular pressure and glaucoma progression:results from the Early Manifest Glaucoma Trial[J].Arch Ophthalmol,2002,120 (10):1268-1279.
-
8Leske MC,Heijl A,Hussein M,et al.Factors for glaucoma progression and the effect of treatment:the Early Manifest Glaucoma Trial[J].Arch Ophthalmol,2003,121 (1):48-56.
-
9Hamacher T,Schinzel M,Sch(o)lzel-Klatt A,et al.Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies[J].Br J Ophthalmol,2004,88 (10):1295-1298.
-
10Dunker S,Schmucker A,Maier H.Tolerability,quality of life,and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol[J].Adv Ther,2007,24(2):376-386.
二级参考文献20
-
1石晶明,蒋幼芹,葛坚,刘磊,孙兴怀,陈晓明,余敏斌,孙丽,郭文毅,李茅.派立明与贝特舒联合用药对青光眼和高眼压症疗效的多中心研究[J].中国实用眼科杂志,2004,22(12):969-972. 被引量:6
-
2余敏斌,方敏,葛坚,黄圣松.1%派立明滴眼液联合0.25%贝特舒混悬液的临床降眼压疗效及安全性观察[J].眼科学报,2005,21(4):137-140. 被引量:4
-
3Baudouin C, Garcher C, Haouat N, et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma [ J ]. Ophthalmology, 1994, 101(3) :454 -460.
-
4Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study [ J ]. Invest Ophthalmol Vis Sci, 2004, 45 (5) : 1360 - 1368.
-
5Berdy GJ, Abelson MB, Smith LM, et al. Preservative - free artificial tear preparations. Assessment of corneal epithelial toxic effects[J]. Arch Ophthalmol, 1992, 110 (4) : 528 -532.
-
6Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications [ J ]. Cornea, 2004, 23 (5) : 490 - 496.
-
7Lark KK, Pasha AS, Yan X, et al. The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts [J]. J Glaucoma, 1999, 8(1) : 72 -76.
-
8Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells [ J ]. Invest Ophthalmol Vis Sci, 2001,42(3) : 642 -652.
-
9De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells [ J ]. Curr Eye Res, 2000, 20 (2) : 85 - 94.
-
10Doughty MJ. Twice - daily use of a chlorobutanol -preserved artificial tear on rabbit corneal epithelium assessed by scanning electron microscopy [ J]. Ophthalmic Physiol Opt, 1992, 12(4):457-466.
共引文献15
-
1王祎成.青光眼的药物治疗研究[J].求医问药(下半月),2013(2):533-534.
-
2陈晓明,刘旭阳.抗青光眼药物联合治疗的策略[J].中华眼科杂志,2006,42(11):1047-1050. 被引量:9
-
3毛真,刘杏,钟毅敏,王涛.毛果芸香碱和布林佐胺滴眼液对兔眼表组织的影响[J].中国病理生理杂志,2008,24(11):2251-2256. 被引量:11
-
4刘杏.重视青光眼药物和滤过手术对眼表的影响[J].眼科,2009,18(1):6-9. 被引量:6
-
5毛真,刘杏,钟毅敏,黄晶晶,王涛,李媚,肖辉.短期局部应用抗青光眼药物对眼表影响的前瞻陛研究[J].眼科,2009,18(1):46-50. 被引量:14
-
6王一平,唐丹.原发性开角型青光眼局部药物治疗及护理进展[J].护理研究(上旬版),2009,23(3):584-585. 被引量:4
-
7余芬芬,钟毅敏,李媚,毛真,郭歆星,杨莎莎,曹丹,肖辉,刘杏.聚乙二醇滴眼液对拉坦前列腺素眼表毒性的中和作用[J].中华实验眼科杂志,2013,31(3):227-232. 被引量:3
-
8余芬芬,刘杏,钟毅敏,毛真,郭歆星,李媚,曹丹,陈翔熙.透明质酸钠对兔含苯扎氯铵溴莫尼定眼表毒性保护作用的研究[J].中华眼科杂志,2013,49(11):973-980. 被引量:4
-
9戴冬姝,刘玉青.维生素A棕榈酸酯眼用凝胶预防抗青光眼药物眼表损伤的作用[J].中国中医眼科杂志,2015,25(3):175-179. 被引量:5
-
10李斌,孔宁.玻璃酸钠联合普拉洛芬对苯扎氯铵诱导新西兰兔干眼的改善作用[J].今日药学,2017,27(2):99-101. 被引量:2
同被引文献24
-
1王宁利,梁远波,乔利亚,李树宁,王洪涛,王华.拉坦前列腺素降眼压作用与小梁网房水排出途径的关系探讨[J].中华眼科杂志,2006,42(4):341-343. 被引量:23
-
2Tressler CS. A 12-week,randomized,double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy[J]. European Journal of Ophthalmol- ogy,2010,20(4) :708-718.
-
3Johnson TV,Fan S,Zhan G,et al. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and tim- olol in participants with ocular hypertension:A comparison of 1 and 6 weeks of treatment[J]. Journal of Glaucoma, 2010,19(6) :356-364.
-
4Anastasios GP,Konstas G,Holl6 DG,et al. 24-hour effi- cacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high- pressure exfoliation syndrome and glaucoma[J]. The British Journal of Ophthalmology, 2013,97 (7) : 857-861.
-
5梅海峰,邢怡桥,杨安怀,张少维.硅油填充术后继发性青光眼162例[J].眼科新进展,2008,28(2):160-160. 被引量:12
-
6林朝斌,徐国兴,陈伟芳,吴晓民,王秀春,朱梅红.原发性开角型青光眼治疗后24h眼压波动的临床观察[J].中国实用眼科杂志,2009,27(11):1279-1282. 被引量:6
-
7刘梅,赖铭莹,成洪波,黄丽娜,邓丽红,贺温玲.拉坦噻吗滴眼液治疗青光眼临床疗效观察[J].国际眼科杂志,2011,11(2):358-359. 被引量:2
-
8黄海荔,孙兴怀,肖明.三种前列腺素类滴眼液治疗原发性开角型青光眼的降眼压效果比较[J].中华眼科杂志,2011,47(2):109-113. 被引量:16
-
9杨扬帆,余敏斌.青光眼固定配方复合制剂的发展和现状[J].中华眼科杂志,2011,47(2):176-180. 被引量:4
-
10沈勇,谷成胜,肖贤柳.复合小梁切除术治疗抗青光眼术后眼压不降的临床体会[J].四川医学,2011,32(3):411-412. 被引量:3
引证文献3
-
1沈琪敏,姚克,施晓琴.拉坦前列腺素联合马来酸噻吗洛尔对原发性开角型青光眼患者24h眼压及眼血流的影响[J].中国现代医生,2015,53(5):74-77. 被引量:16
-
2许薇琦,张剑虹.硅油填充术后继发性青光眼局部降眼压药物治疗效果观察[J].中国实用眼科杂志,2016,34(11):1195-1198. 被引量:4
-
3许思思,白鹏.复合制剂在原发性开角型青光眼中的应用效果观察[J].海峡药学,2017,29(6):183-184. 被引量:5
二级引证文献24
-
1李璇,刘茁,何志,蔡维,张洪洋,陈建斌.马来酸噻吗洛尔联合拉坦前列腺素治疗高眼压型开角型青光眼的效果[J].现代生物医学进展,2015,15(25):4967-4970. 被引量:8
-
2文华,赵小琴.开角型青光眼患者治疗前、后眼底血流状态的变化[J].海南医学院学报,2016,22(5):506-508. 被引量:6
-
3李杨林.缺血性眼病眼部动脉血流改变的临床对比观察[J].中国伤残医学,2016,0(11):22-24. 被引量:2
-
4席桂荣,张秀艳,齐美华,林芳.拉坦前列腺素对于开角型青光眼的降眼压疗效观察[J].中国实用医药,2016,11(27):173-174. 被引量:2
-
5李建超,彭俊,曾志成,姚小磊,徐剑,彭抿,江冰,谭涵宇,彭清华.原发性开角型青光眼患者眼血流动力学的改变及与中医证型关系的研究[J].湖南中医药大学学报,2016,36(12):27-30. 被引量:21
-
6王佳.曲伏前列素滴眼液对开角型青光眼眼压、血流动力学的影响及其相关性分析[J].临床眼科杂志,2017,25(4):296-298. 被引量:18
-
7贾新山.拉坦前列素滴眼液临床应用研究进展[J].中国药业,2017,26(18):95-96. 被引量:3
-
8史怀英.治疗眼外伤继发青光眼患者不同手术方式的价值比较[J].中外医学研究,2017,15(27):23-25. 被引量:4
-
9姬明利,赵奎卿.联合用药对高眼压型POAG患者视盘参数及视网膜神经纤维层厚度的影响[J].国际眼科杂志,2017,17(12):2292-2295. 被引量:7
-
10吴书,张开颜,陈炳荣,王玲玲.拉坦前列素与噻吗洛尔不同联用方案治疗原发性开角型青光眼的临床观察[J].中国药房,2018,29(6):809-812. 被引量:12
-
1苗壮.不同种类前列腺素类滴眼液治疗原发性开角型青光眼的降眼压效果[J].中国伤残医学,2016,0(10):102-103. 被引量:6
-
2刘宏伟.前列腺素也能治疗青光眼[J].保健医苑,2013(8):18-19.
-
3施爱群.青光眼患者您用对眼药了吗?(下)[J].中老年保健,2011(8):26-27.
-
4刘梅,赖铭莹,成洪波,黄丽娜,邓丽红,贺温玲.拉坦噻吗滴眼液治疗青光眼临床疗效观察[J].国际眼科杂志,2011,11(2):358-359. 被引量:2
-
5贾淑琴,徐瑞.适利达联合噻吗心安滴眼液治疗开角型青光眼疗效观察[J].河北联合大学学报(医学版),2014,16(2):225-225. 被引量:2
-
6宋汝庸,陈积中.锯齿缘断离术式选择与疗效的关系[J].中国实用眼科杂志,1995,13(10):621-623. 被引量:2
-
7宋汝庸,陈积中.锯齿缘断离术式选择与疗效的关系[J].临床眼科杂志,1995,3(1):23-25.
-
8杨洪涛.不同种类前列腺素类滴眼液治疗原发性开角型青光眼的降眼压效果对比[J].中国医药导报,2014,11(18):70-73. 被引量:10
-
9杨燕宁,胡杨,蔡明高,邢怡桥,朱研,江双红,武犁.巩膜瓣下深层纵形小梁切除术的超声生物显微镜观察[J].中国医学影像技术,2007,23(5):671-673.
-
10奚婷,张春元.拉坦前列素联合马来酸噻吗洛尔的降眼内压效果观察[J].中国继续医学教育,2016,8(29):155-157. 被引量:1